BRAINSTORM CELL THERAPEUTICS INC. Total Liabilities
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) had Total Liabilities of $12.38 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-14
- 2026-06-30: Liabilities $12.38M.
- 2026-03-31: Liabilities $11.76M.
- 2025-12-31: Liabilities $11.01M.
- 2025-09-30: Liabilities $9.07M.
| Period end | Liabilities | Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $12.38M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $11.76M 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $11.01M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $9.07M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $8.62M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $11.03M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $9.60M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $8.08M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $9.21M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $8.90M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $9.07M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $8.26M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $9.63M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $12.71M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $11.47M 10-K · filed 2024-04-01 | |
| 2022-09-30 | $11.87M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $11.11M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $11.30M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $9.94M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $9.61M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $12.06M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $12.37M 10-Q · filed 2021-04-26 | |
| 2020-12-31 | $15.79M 10-K · filed 2022-03-28 | |
| 2020-09-30 | $6.71M 10-Q · filed 2020-10-15 | |
| 2020-06-30 | $9.40M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $9.06M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $18.76M 10-K · filed 2021-02-04 | |
| 2019-09-30 | $14.59M 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $13.38M 10-Q · filed 2019-08-13 | |
| 2019-03-31 | $11.53M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $6.21M 10-K · filed 2020-02-18 | |
| 2018-09-30 | $3.79M 10-Q · filed 2018-10-29 | |
| 2018-06-30 | $8.15M 10-Q · filed 2018-07-23 | |
| 2018-03-31 | $5.58M 10-Q · filed 2018-05-14 | |
| 2017-12-31 | $5.54M 10-K · filed 2019-04-01 | |
| 2016-12-31 | $864.00K 10-K · filed 2018-03-08 | |
| 2015-12-31 | $2.95M 10-K · filed 2017-03-29 | |
| 2015-09-30 | $2.84M 10-Q · filed 2015-11-16 | |
| 2015-06-30 | $2.53M 10-Q · filed 2015-08-13 | |
| 2015-03-31 | $2.73M 10-Q · filed 2015-05-14 | |
| 2014-12-31 | $3.24M 10-K · filed 2016-03-09 | |
| 2014-09-30 | $2.50M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $1.92M 10-Q · filed 2014-08-12 | |
| 2014-03-31 | $3.33M 10-Q · filed 2014-05-13 | |
| 2013-12-31 | $1.99M 10-K · filed 2015-03-26 | |
| 2013-09-30 | $1.68M 10-Q · filed 2013-11-14 | |
| 2013-06-30 | $1.44M 10-Q · filed 2013-08-14 | |
| 2013-03-31 | $1.27M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $1.16M 10-K · filed 2014-03-27 | $1.33M 10-K · filed 2013-03-14 |
| 2012-09-30 | $1.26M 10-Q · filed 2012-11-13 | |
| 2012-06-30 | $1.60M 10-Q/A · filed 2012-08-29 | |
| 2012-03-31 | $1.43M 10-Q · filed 2012-05-11 | |
| 2011-12-31 | $1.26M 10-K · filed 2013-03-14 | |
| 2011-09-30 | $909.00K 10-Q · filed 2011-11-14 | |
| 2011-06-30 | $1.37M 10-Q/A · filed 2011-09-07 | |
| 2010-12-31 | $1.55M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |